News 
Market Data 
Discover
Replies to post #464462 on Anavex Life Sciences Corp (AVXL)
Review Targeting senescent cells in translational medicine
Marta Paez-Ribes1,†, Estela González-Gualda1,†, Gary J Doherty2& Daniel Muñoz-Espín1,*
Abstract
Organismal ageing is a complex process driving progressive impairment of functionality and regenerative potential of tissues. Cellular senescence is a state of stable cell cycle arrest occurring in response to damage and stress and is considered a hallmark of ageing. Senescent cells accumulate in multiple organs during ageing, contribute to tissue dysfunction and give rise to pathological manifestations.Senescence is therefore a defining feature of a variety of human age-related disorders, including cancer, and targeted elimination of these cells has recently emerged as a promising therapeutic approach to ameliorate tissue damage and promote repair and regeneration. In addition, in vivo identification of senescent cells has significant potential for early diagnosis of multiple pathologies.Here, we review existing senolytics, small molecules and drug delivery tools used in preclinical therapeutic strategies involving cellular senescence, as well as probes to trace senescent cells. We also review the clinical research landscape in senescence and discuss how identifying and targeting cellular senescence might positively affect pathological and ageing process,
Activation of SG1-mediated autophagy by AVXL drug could have much broader application than just neurological disorders!!
AI
